BrainStorm Cell Therapeutics has had a meeting with the U.S. Food and Drug Administration (FDA) seeking an agreement on its plans for a confirmatory Phase 3b trial of NurOwn, a cell-based treatment the company is developing for amyotrophic lateral sclerosis (ALS). The main goal of the meeting,…
A few weeks before Christmas Day in 2018, my late husband, Jeff, and I sat side by side on the edge of our bed, preparing to create the most meaningful Christmas gifts we’d ever given. Laid out beside us on the bed were four children’s storybooks, each with a Christmas…
“The essence of trauma is powerlessness.” This quote from Christian trauma therapist Colleen Ramser grabbed my attention, because I often feel powerless as a caregiver for my husband, Todd, who is paralyzed by ALS. We’ve been having a rough week. Todd’s shower aide called in sick a…
Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress chronic and sustained inflammation — will now be exclusively marketed by Dr. Reddy’s Laboratories in the U.S., Canada, and the U.K., as well as in the European Union, should…
The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…
One important habit I enjoy doing every day is keeping up with the latest ALS-related news and research. But every once in a while, I come across an article that has me muttering, “Was this research even needed?” And more often than not, I answer my own question with, “Well,…
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the oral therapy for six months led to “meaningful slowing of disease progression” in people with amyotrophic lateral sclerosis (ALS), the company said in a press release announcing top-line…
Genetic and clinical factors that can influence how amyotrophic lateral sclerosis (ALS) progresses were identified in a recent analysis of data from PRECISION-ALS, a large European research project. Consistent with known risk factors for ALS progression, C9ORF72 genetic mutations, bulbar-onset disease, and faster functional declines were linked…
Colchicine, an anti-inflammatory medication used to treat gout, was safe, but did not significantly slow the progression of amyotrophic lateral sclerosis (ALS) in a small Phase 2 clinical trial. While some clinical measures suggested a possible benefit of a low dose of colchicine in slowing disease progression and extending…
A couple days ago, as I was dishing up our family dinner, I popped a piece of chicken in my mouth and accidentally aspirated, drawing a small piece of chicken or phlegm into my lungs. I tried to cough it up, but wasn’t getting it out. I winced and pounded…
Get regular updates to your inbox.
